Yellow fever vaccine: Comparison of the neurovirulence of new 17D-204 Stamaril™ seed lots and RK 168-73 strain

Moulin, Jean-Claude; Silvano, Jérémy; Barban, V.; Riou, Patrice; Allain, Caroline

doi:10.1016/j.biologicals.2013.04.005

Cited by 11 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the NS4b V115A in DENV‐2 strain D2S10 (together with the K122I mutation in the envelope protein) causes mortality at 10‐fold lower inoculum in mice than in wild‐type virus . Similar to DENV, adapting the YFV 17D to Vero cells resulted in acquisition of the I113M mutation in the NS4b . The NS4b V98I mutation was associated with more aggressive pathogenesis and lethal viscerotropic disease in the YFV Asibi hamster model .…”

Section: Expression Post‐translational Processing Structure Localimentioning

confidence: 99%

Flaviviral NS4b, chameleon and jack‐in‐the‐box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention

Zmurko

Neyts

Dallmeier

2015

Reviews in Medical Virology

View full text Add to dashboard Cite

SummaryDengue virus and other flaviviruses such as the yellow fever, West Nile, and Japanese encephalitis viruses are emerging vector‐borne human pathogens that affect annually more than 100 million individuals and that may cause debilitating and potentially fatal hemorrhagic and encephalitic diseases. Currently, there are no specific antiviral drugs for the treatment of flavivirus‐associated disease. A better understanding of the flavivirus–host interactions during the different events of the flaviviral life cycle may be essential when developing novel antiviral strategies. The flaviviral non‐structural protein 4b (NS4b) appears to play an important role in flaviviral replication by facilitating the formation of the viral replication complexes and in counteracting innate immune responses such as the following: (i) type I IFN signaling; (ii) RNA interference; (iii) formation of stress granules; and (iv) the unfolded protein response. Intriguingly, NS4b has recently been shown to constitute an excellent target for the selective inhibition of flavivirus replication. We here review the current knowledge on NS4b. © 2015 The Authors. Reviews in Medical Virology published by John Wiley & Sons Ltd.

show abstract

Section: Expression Post‐translational Processing Structure Localimentioning

confidence: 99%

Flaviviral NS4b, chameleon and jack‐in‐the‐box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention

Zmurko

Neyts

Dallmeier

2015

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Furthermore, mice are used to test batches of the 17D vaccine to verify safety prior to evaluation in nonhuman primates (NHPs) and people [29].…”

Section: Micementioning

confidence: 99%

Role Of Animal Models In The Study Of Yellow Fever Disease And Vaccine

Liu¹,

Gezmis²

2022

J Stud Res

View full text Add to dashboard Cite

Yellow fever (YF) is a mosquito-borne disease caused by the neurovirulent and viscerotropic YF virus (YFV). Fevers, nausea, body aches, and fatigue commonly characterize the disease, with around 15% of infected people entering fatal phases. The mosquitos that typically carry YFV roam over Africa and South America, where approximately 1 billion people among 46 countries are at risk. A live-attenuated vaccine, strain 17D, was developed in the 1930s and used ever since. However, cases of adverse events presented after the administration of YF vaccines. Additionally, certain groups cannot take the YF vaccine due to its contraindications. Previous advancements in understanding the YFV and developing the vaccine are attributable to the use of animal models. Model organisms are also critical in implementing current modifications to the YF vaccine. This review will discuss these topics in greater detail with a heavy emphasis on the contribution of animal models to the study of YF, along with alternative methods to maximizing global immunity against YF.

show abstract

“…22 In 2010, Sanofi-Pasteur tested two new candidate WSLs at passage 233 to replace the YF17D-204 PV26/S706 (passage 234) that had been in continuous manufacturing use for 20 years and found no significant differences. 23 …”

Section: Sanofi-pasteur 17d-204 Stamaril™mentioning

confidence: 99%

Evaluating the safety and immunogenicity of yellow fever vaccines: a systematic review

Thomas

2015

VDT

View full text Add to dashboard Cite

Purpose: To review the safety and immunogenicity of yellow fever vaccines. Literature search: The Cochrane Library (including the Cochrane CENTRAL Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and the NHS Database of Abstracts of Reviews of Effects); MEDLINE; EMBASE; BIOSIS Previews; Global Health; CAB Abstracts; and the Lilacs Database of Latin American and Caribbean literature were searched for individual studies and systematic reviews through January 1, 2015. Results: Six yellow fever vaccines are currently produced, and they are effective against all seven yellow fever virus strains. There is a 99.2% homology of the genome sequences of the six current vaccines. Four systematic reviews identified very small numbers of serious adverse events. A systematic review (updated) of all published cases identified 133 serious adverse events that met the Brighton Collaboration criteria: 32 anaphylactic, 42 neurologic (one death), 57 viscerotropic (25 deaths), and two of both neurologic and viscerotropic SAEs. The Sanofi Pasteur Global Pharmacovigilance database reported 276 million doses of Stamaril™ distributed worldwide and identified 12 reports of yellow fever vaccine-associated viscerotropic disease (YEL-AVD), 24 of yellow fever vaccine-associated neurologic disease (YEL-AND), and 33 reports of anaphylaxis (many already published). The Biomanguinhos manufacturer's database reported 110 million doses distributed worldwide between 1999 and 2009, and the rate of YEL-AND was estimated at 0.084/100,000 doses distributed and YEL-AVD at 0.02/100,000 doses distributed. Conclusion: Reports of serious adverse events are mostly from travelers from developed countries, and there is likely serious underreporting for developing countries. On the basis of the published reports, the yellow fever vaccines are very safe and probably provide life-long immunity.

show abstract

Yellow fever vaccine: Comparison of the neurovirulence of new 17D-204 Stamaril™ seed lots and RK 168-73 strain

Cited by 11 publications

References 14 publications

Flaviviral NS4b, chameleon and jack‐in‐the‐box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention

Flaviviral NS4b, chameleon and jack‐in‐the‐box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention

Role Of Animal Models In The Study Of Yellow Fever Disease And Vaccine

Evaluating the safety and immunogenicity of yellow fever vaccines: a systematic review

Contact Info

Product

Resources

About